Advertisement
Research Article| Volume 7, ISSUE 3, P521-532, July 1991

Anticonvulsant Agents

  • Fritz E. Dreifuss
    Correspondence
    Address reprint requests to: Fritz E. Dreifuss, MD, FRCP, FRACP, Department of Neurology, School of Medicine, University of Virginia, Center for Health Sciences, Box 394, Charlottesville, VA 22908
    Affiliations
    Professor, Department of Neurology, the University of Virginia, School of Medicine, Health Sciences Center, Charlottesviile, Virginia
    Search for articles by this author
DOI:https://doi.org/10.1016/S0749-0704(18)30294-X
Anticonvulsant Agents
Previous ArticleAntiarrhytmic: Agents
Next ArticleAnticoagulants and Thrombolytics
      This paper is only available as a PDF. To read, Please Download here.
      Anticonvulsant agents are often placed into two groups: those that complicate drug administration in a relatively predictable manner and those that cause idiosyncratic reactions that are relatively unpredictable, unheralded, and frequently quite severe. This article examines the toxic effects of anticonvulsant drugs used to treat diseases commonly seen in the intensive care unit (ICU), where the situation is complicated by the severity of the primary pathologic condition, which frequently involves the use of drugs that may have a significant effect on the blood levels and efficacy of the anticonvulsant drugs. Complications associated with the route of drug administration and their signs and symptoms are also discussed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Critical Care Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Aicardi J.
        Status epilepticus.
        Epilepsy in Children. Raven Press, New York1986: 240-259
        • Andrewes D.G.
        • Bullen J.G.
        • Tolinson L.
        • et al.
        A comparative study of cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy.
        Epilepsia. 1986; 27: 128-134
        • Asconape J.J.
        • Penry J.K.
        Use of antiepileptic drugs in the presence of liver and kidney diseases: A review.
        Epilepsia. 1982; 23: S65-S79
        • Bauer L.A.
        Interference of oral phenytoin absorption by continuous nasogastric feedings.
        Neurology (NY). 1982; 32: 570-572
        • Becker D.M.
        • Kramer S.
        The neurological manifestations of prophyria: A review.
        Medicine. 1977; 56: 411-423
        • Bennett W.M.
        Altering drug dose in patients with diseases of kidney and liver.
        in: Anderson R.J. Schrier R.W. Clinical Use of Drugs in Patients with Kidney and Liver Disease. WB Saunders, Philadelphia1981: 16-29
        • Cacek T.A.
        Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food.
        Ther Drug Monit. 1986; 8: 166-171
        • Chadwick D.
        Drug withdrawal and epilepsy: When and how?.
        Drugs. 1988; 35: 579-583
        • Cloyd J.C.
        • Gumnit R.J.
        • McLain L.W.
        Status epilepticus: The role of intravenous phenytoin.
        JAMA. 1980; 244: 1479-1481
      10. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures.
        Epilepsia. 1981; 22: 489-501
      11. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes.
        Epilepsia. 1989; 30: 389-399
      12. Committee on Drugs, American Academy of Pediatrics: Behavioral and cognitive effects of anticonvulsants.
        Pediatrics. 1985; 76: 644-647
        • Dean J.C.
        • Penry J.K.
        Discontinuation of antiepileptic drugs.
        in: Levy R.H. Antiepileptic Drugs. ed 3. Raven Press, New York1989: 133-142
        • Delgado-Escueta A.V.
        • Wasterlain C.
        • Treiman D.M.
        • et al.
        Current concepts in neurology. Management of status epilepticus.
        N Engl J Med. 1982; 306: 1337-1340
        • Dreifuss F.E.
        Bromides.
        in: Levy R.H. Dreifuss F.E. Mattson R.H. Antiepileptic Drugs. ed 3. Raven Press, New York1989: 877-879
        • Dreifuss F.E.
        • Santilli N.
        • Langer D.H.
        • et al.
        Valproic acid hepatic fatalities: A retrospective review.
        Neurology. 1987; 37: 379-385
        • Earnest M.P.
        • Marx J.A.
        • Drury L.R.
        Complications of intravenous phenytoin for acute treatment of seizures.
        JAMA. 1983; 249: 762-765
        • Farwell J.R.
        • Lee Y.J.
        • Hirtz D.C.
        • et al.
        Phenobarbital and febrile seizures: Effects on intelligence and on seizure recurrence.
        N Engl J Med. 1990; 322: 364-369
        • Gastaut H.
        Definitions.
        Dictionary of Epilepsy, Part I. World Health Organization, Geneva1973
        • Gerson W.T.
        • Fine D.G.
        • Spielberg S.P.
        • et al.
        Anticonvulsant-induced aplastic anemia: Increased susceptibility to toxic metabolites in vitro.
        Blood. 1983; 61: 889-893
        • Gram L.
        • Bentsen K.D.
        Hepatic toxicity of antiepileptic drugs: Review.
        Acta Neurol Scand. 1983; S97: 81-90
        • Guidry J.R.
        • Eastwood T.F.
        • Curry S.C.
        Phenytoin absorption in volunteers receiving selected enteral feeds.
        West J Med. 1989; 150: 659-661
        • Hansten P.D.
        • Horn J.R.
        Carbamazepine-induced water intoxication: Drugs that may increase the risk.
        Drug Interact Newslett. 1987; 7: 53-56
        • Harmon C.E.
        • Portanova J.P.
        Drug-induced lupus: Clinical and serological studies.
        Clin Rheumatic Dis. 1982; 8: 121-135
        • Holtz L.
        • Milton J.
        • Sturek J.K.
        Compatibility of medication with enteral feedings.
        J Parenter Enteral Nutr. 1987; 11: 183-186
        • Jeavons P.M.
        Non-dose-related side-effects of valproate.
        Epilepsia. 1984; 25: S50-S55
        • Johannessen S.I.
        • Henriksen O.
        • Munthe-Kaas A.W.
        Need for antiepileptic drug preparations other than oral.
        in: Morselli P.L. Pippenger C.E. Penry J.K. Antiepileptic Drug Therapy in Pediatrics. Raven Press, New York1983: 339-347
        • Johnson R.T.
        • Richardson E.P.
        The neurological manifestations of systemic lupus erythematosus.
        Medicine. 1968; 47: 337-369
        • Kilarski D.J.
        • Buchanan C.
        • Von Behren L.
        Soft-tissue damage associated with intravenous Phenytoin.
        N Engl J Med. 1984; 311: 1136-1187
        • Leppik I.E.
        Double-blind study of lorazepam and diazepam in status epilepticus.
        JAMA. 1983; 249: 1452-1454
        • Levine M.
        • Jones M.W.
        • Sheppard I.
        Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin.
        Neurology. 1985; 35: 562-565
        • Lockman L.A.
        Status Epilepticus.
        in: Morselli P.L. Pippenger C.E. Penry J.K. Antiepileptic Drug Therapy in Pediatrics. Raven Press, New York1983: 173-180
        • Lowenstein D.H.
        • Aminoff M.J.
        • Simon R.P.
        Barbiturate anesthesia in the treatment of status epilepticus: Clinical experience with 14 patients.
        Neurology. 1988; 38: 395-400
        • Mason J.W.
        Amiodarone.
        N Engl J Med. 1987; 316: 455-466
        • Maynard G.A.
        • Jones K.M.
        • Guidry J.R.
        Phenytoin absorption in volunteers receiving selected enteral feedings.
        West J Med. 1989; 150: 659-661
        • Mizrahi E.M.
        Neonatal seizures: Problems in diagnosis and classification.
        Epilepsia. 1987; 28: S46-S55
        • Olney J.W.
        • Collins R.C.
        • Sloviter R.S.
        Excitotoxic mechanisms of epileptic brain damage.
        in: Delgado-Escueta A.V. Ward A.A. Woodbury D.M. Basic Mechanisms of the Epilepsies. Raven Press, New York1986: 857-877
        • Rashkin M.C.
        • Young J.C.
        • Penovich P.
        Pentobarbital treatment of refractory status epilepticus.
        Neurology. 1987; 37: 500-503
        • Raworth R.E.
        • Birchell G.
        Sodium valproate and platelet count.
        Lancet. 1978; 1: 670
        • Reeme P.D.
        • Day D.L.
        Phenytoin injection precautions.
        Clin Pharm. 1985; 4: 618-619
        • Rettie A.E.
        • Rettenmeier A.W.
        • Howald W.N.
        • et al.
        Cytochrome P-450-catalyzed formation of delta-4-VPA, a toxic metabolite of valproic acid.
        Science. 1987; 235: 890-892
        • Reynolds N.C.
        • Miska R.M.
        Safety of anticonvulsants in hepatic porphyrias.
        Neurology. 1981; 31: 480-484
        • Richards W.
        • Church J.A.
        • Brent D.K.
        Theophylline-associated seizures in children.
        Ann Allergy. 1985; 54: 276-279
        • Saklad J.J.
        • Graves R.H.
        • Sharp W.P.
        Interaction of oral phenytoin with enteral feedings.
        J Parenter Enteral Nutr. 1986; 10: 322-323
        • Scheuer M.L.
        The medical patient with epilepsy.
        in: Resor S. Kutt H. Medical Management of Epilepsy. Marcel Dekker, New York1991 (in press)
        • Schmidt D.
        Disorders of the kidneys.
        in: Schmidt D. Adverse Effects of Antiepileptic Drugs. Raven Press, New York1982: 111
        • Snead III., O.C.
        • Hosey L.C.
        Exacerbation of seizures in children by carbamazepine.
        N Engl J Med. 1985; 313: 916-921
        • Spengler R.F.
        • Arrowsmith J.B.
        • Kilarski D.J.
        • et al.
        Severe soft-tissue injury following intravenous infusion of phenytoin.
        Arch Intern Med. 1988; 148: 1329-1333
        • Steyfer A.E.
        Upper extremity injuries due to medications.
        J Hand Surg. 1987; 12A: 744-750
        • Trimble M.R.
        Anticonvulsant drugs and cognitive function: A review of the literature.
        Epilepsia. 1987; 28: S37-S45
        • Urbano A.M.
        Phenytoin-quinidine interaction in a patient with recurrent ventricular tachyarrhythmias.
        N Engl J Med. 1983; 308: 225
        • Vajda F.JE.
        • Mihaly G.W.
        • Miles J.L.
        • et al.
        Rectal administration of sodium valproate in status epilepticus.
        Neurology. 1978; 28: 897-899
        • Weinstein A.
        Drug-induced systemic lupus erythematosus.
        Prog Clin Immunol. 1980; 4: 1-21
        • Worden J.P.
        • Wood C.A.
        • Workman C.H.
        Phenytoin and nasogastric feedings.
        Neurology. 1984; 34: 132
        • Wyllie E.
        • Wyllie R.
        • Cruse R.P.
        • et al.
        Pancreatitis associated with valproic acid therapy.
        Am J Dis Child. 1948; 138: 912-914
        • Zimmerman H.
        • Ishak K.
        Valproate-induced hepatic injury: Analyses of 23 fatal cases.
        Hepatology. 1982; 2: 591-597

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0749-0704(18)30294-X

      Copyright

      © 1991 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX